Table 3.
Mannose targets and related diseases
| Mannose Target | Associated in disease |
|---|---|
| Mannose-6-phosphate isomerase (MPI) | Tumor cell apoptosis [132, 133] |
| Hepatic fibrosis [134]. | |
| Macrophage Mannose receptor 1 (MRC1/CD206) | Allergen-induced lung inflammation [135]. |
| Regulator of (Meta)Inflammation [136]. | |
| Predicts Prognosis in Community-acquired Pneumonia [137]. | |
| Targeting protein for Xklp2 (TPX2) | Tumor angiogenesis in pancreatic cancer [138]. |
| Prognostic marker and therapeutic target for gastric cancer [139]. | |
| Mannose-binding protein C (MBL2) | Biomarker for Many Human Diseases [140, 141]. |
| Role in the susceptibility to infections [142]. | |
| CD81 antigen (CD81) | A tumor target [143–145]. |
| Mannan-binding lectin serine protease 2 (MASP2) | MASP-2 deficiency and tuberculosis [146]. |
| Post-ischemic brain injury [147] | |
| Roles in the development of lupus-like glomerulonephritis [148]. | |
| N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase, (NAGPA) | Human stuttering mutations [149, 150]. |
| Regulatory-associated protein of mTOR, (RPTOR) | Peripheral blood and breast cancer [151]. |
| Rheumatoid Arthritis [152]. | |
| Autophagy and Apoptosis in Renal Carcinoma [153]. | |
| Squamous cell carcinoma [154]. | |
| Hsp90 co-chaperone Cdc37 (CDC37) | Neurodegenerative Diseases [155]. |
| Agent in longevity [156]. | |
| Aurora kinase A (AURKA) | Hepatocellular Carcinoma [157]. |
| The modulator of Lung Fibrosis [158]. | |
| The target for GC treatment [159]. | |
| Lung adenocarcinoma [160]. | |
| Cation-dependent Mannose-6-phosphate receptor (M6PR) | Regulator of T cell immunity [161]. |
| Controlling tumor-infiltrating innate immune cells [162]. | |
| Involvement in sperm cell-HIV-1 interaction [163]. | |
| Mannan-binding lectin serine protease 1Mannan-binding lectin serine protease 1 (MASP1) | Support the hemostatic system [164]. |
| Functions as enzymes and as pattern recognition molecules [165]. | |
| Promote the fibrinolytic activity destabilizes the clot [166]. | |
| Importin subunit beta-1 (KPNB1) | Target for Glioblastoma [167]. |
| Prognostic biomarker in Colorectal cancer patients [168]. | |
| The therapeutic target for Prostate cancer [169]. | |
| Histone-lysine N-methyl transferase EZH2, (EZH2) | Increase chemosensitivity by inhibiting cell viability in lung cancer cells [170]. |
| Therapeutic Target for Kidney Diseases [171]. | |
| Cancer epigenetics [172]. | |
| Epithelioid sarcoma and follicular lymphoma [173]. | |
| Polycomb protein EED, (EED) | Malformation of the dentate gyrus and intellectual disability [174]. |
| Regulation of epithelial-mesenchymal transition of cancer cells [175]. | |
| Histone-lysine N-methyltransferase EZH1 (EZH1) | Genetic markers for Thyroid tumors with EZH1 mutations [176]. |
| Effective biomarker for Triple-negative breast cancer (TNBC) [177]. | |
| GDP-Mannose 4,6 dehydratase (GMDS) | Biomarker for lung adenocarcinoma [178]. |
| Colorectal cancer and GMDS mutation [179]. | |
| Perilipin-3 (PLIN3) | Response to Radiation Therapy of Prostate Cancer [180]. |
| Biomarker for Type2 Diabetes Mellites [181]. | |
| The therapeutic target for Non-alcoholic fatty liver disease [182]. | |
| Diagnostic and prognostic biomarkers in Renal cancer [183]. | |
| Heat shock protein HSP 90-alpha (HSP90AA1) | Therapeutic target for peri-implantitis. [184]. |
| Repairing DNA damage and chemoresistance of ovarian cancer cells [185]. | |
| Biomarker for Oral Squamous Cell Carcinoma [186]. | |
| As regulatory axis in osteosarcoma [187]. |